Is GeoVax Labs, Inc. (GOVX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 138.4% / 30% | 16.6% / 30% | 4.38% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 138.4% / 33% | 16.6% / 33% | 4.38% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 67.5% / 33% | 8.1% / 33% | 4.38% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 138.4% / 33% | 16.6% / 33% | 4.38% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 67.5% / 33% | 8.1% / 50% | 4.38% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -761.6% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -377.4% | |
| Return on Assets (ROA) | -178.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$25M |
| Free Cash Flow | -$25M |
| Current Ratio | 3.6 |
| Total Assets | $8M |
Price & Trading
| Last Close | $1.41 |
| 50-Day MA | $2.08 |
| 200-Day MA | $11.44 |
| Avg Volume | 143K |
| Beta | 3.9 |
|
52-Week Range
$1.26
| |
About GeoVax Labs, Inc. (GOVX)
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is GeoVax Labs, Inc. (GOVX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), GeoVax Labs, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is GeoVax Labs, Inc.'s debt ratio?
GeoVax Labs, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are GeoVax Labs, Inc.'s key financial metrics?
GeoVax Labs, Inc. has a market capitalization of $3M, and revenue of $4M. Return on equity stands at -377.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.